rAAV2/5-hNAGLU
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sanfilippo Syndrome B
Conditions
Sanfilippo Syndrome B
Trial Timeline
Sep 17, 2013 → Nov 27, 2019
NCT ID
NCT03300453About rAAV2/5-hNAGLU
rAAV2/5-hNAGLU is a phase 1/2 stage product being developed by uniQure for Sanfilippo Syndrome B. The current trial status is completed. This product is registered under clinical trial identifier NCT03300453. Target conditions include Sanfilippo Syndrome B.
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03300453 | Phase 1/2 | Completed |
Competing Products
2 competing products in Sanfilippo Syndrome B